Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
GlobeNewswire
· *Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed *
· *Early..
